Legend Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Legend Biotech Corp
LEGN Stock  USD 17.58  0.48  2.66%   
Legend Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Legend Biotech's valuation are provided below:
Gross Profit
132.7 M
Profit Margin
(0.26)
Market Capitalization
3.2 B
Enterprise Value Revenue
2.9311
Revenue
909 M
We have found one hundred twenty available fundamental ratios for Legend Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Legend Biotech's last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 16th of February 2026, Market Cap is likely to drop to about 2.5 B. In addition to that, Enterprise Value is likely to drop to about 2.2 B

Legend Biotech Total Revenue

757.39 Million

Check Legend Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Legend Biotech's main balance sheet or income statement drivers, such as Tax Provision of 22.8 M, Depreciation And Amortization of 28.2 M or Interest Expense of 26.1 M, as well as many indicators such as Price To Sales Ratio of 5.18, Dividend Yield of 0.0 or PTB Ratio of 3.12. Legend financial statements analysis is a perfect complement when working with Legend Biotech Valuation or Volatility modules.
  
Build AI portfolio with Legend Stock
Check out the analysis of Legend Biotech Correlation against competitors.

Legend Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.9 B722.9 M
Slightly volatile
Short and Long Term Debt Total423.4 M403.2 M113.5 M
Slightly volatile
Other Current Liabilities130.7 M188.8 M90.5 M
Slightly volatile
Total Current Liabilities202.9 M319.3 M139 M
Slightly volatile
Other Liabilities6.7 M7.1 M146.4 M
Slightly volatile
Property Plant And Equipment Net126.4 M231.8 M76.4 M
Slightly volatile
Current Deferred Revenue27.3 M42.7 M32.6 M
Pretty Stable
Accounts Payable44.9 M42.8 M14.1 M
Slightly volatile
Cash521.3 M329.8 M273.9 M
Slightly volatile
Non Current Assets Total466.4 M444.2 M142.5 M
Slightly volatile
Non Currrent Assets Other6.6 M7 M13.7 M
Pretty Stable
Other Assets1.091.158.8 M
Pretty Stable
Cash And Short Term Investments718.1 M1.3 B426.3 M
Slightly volatile
Net Receivables84.1 M112.4 M155.2 M
Slightly volatile
Common Stock Shares Outstanding87.5 M105.1 M76 M
Slightly volatile
Long Term Debt Total3.4 M5.8 M2.7 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.9 B722.9 M
Slightly volatile
Non Current Liabilities Total257.3 M404.8 M220.8 M
Slightly volatile
Inventory28.9 M27.5 M6.8 M
Slightly volatile
Other Current Assets9.3 M14.3 M5.7 M
Slightly volatile
Other Stockholder Equity3.3 B3.2 B921.4 M
Slightly volatile
Total Liabilities460.2 M724 M359.8 M
Slightly volatile
Total Current Assets851.1 M1.5 B596.1 M
Slightly volatile
Short Term Debt5.8 M5.5 M1.6 M
Slightly volatile
Intangible Assets210.4 M200.4 M40.2 M
Slightly volatile
Common Stock30.8 K42.5 K25.7 K
Slightly volatile
Property Plant Equipment100.7 M184.9 M69.2 M
Slightly volatile
Common Stock Total Equity24.6 K31.1 K23 K
Slightly volatile
Short Term Investments1 B961.3 M203 M
Slightly volatile
Capital Lease Obligations59.7 M56.8 M16.9 M
Slightly volatile
Property Plant And Equipment Gross158.7 M282 M100.3 M
Slightly volatile
Capital Stock32.1 K42.5 K25.8 K
Slightly volatile
Net Working Capital697.1 M1.2 B449 M
Slightly volatile
Non Current Liabilities Other47.9 K50.4 K181 M
Slightly volatile
Long Term Debt265.1 M346.4 M170.6 M
Slightly volatile

Legend Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization28.2 M26.9 M8.7 M
Slightly volatile
Selling General Administrative165.2 M157.3 M43.5 M
Slightly volatile
Selling And Marketing Expenses178.1 M169.6 M50.8 M
Slightly volatile
Total Revenue757.4 M721.3 M173.6 M
Slightly volatile
Gross Profit474.1 M451.6 M115 M
Slightly volatile
Other Operating Expenses1.1 B1.1 B311.4 M
Slightly volatile
Research Development262.3 M475.6 M159 M
Slightly volatile
Total Operating Expenses840.3 M800.3 M252.7 M
Slightly volatile
Interest Income73.9 M70.4 M18.8 M
Slightly volatile
Reconciled Depreciation14.6 M26.9 M8.7 M
Slightly volatile

Legend Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.1 M1.3 M1.4 M
Slightly volatile
Begin Period Cash Flow1.5 B1.5 B384.2 M
Slightly volatile
Other Cashflows From Financing Activities10.6 M11.2 M27 M
Slightly volatile
Depreciation28.2 M26.9 M8.8 M
Slightly volatile
Capital Expenditures26.9 M16.2 M14.4 M
Slightly volatile
Change To Operating Activities143.4 M136.6 M50.6 M
Slightly volatile
Total Cash From Financing Activities6.2 M6.6 M145.7 M
Slightly volatile
End Period Cash Flow521.2 M329.8 M273.9 M
Slightly volatile
Stock Based Compensation83.2 M79.3 M20.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.185.4561.3511
Slightly volatile
Days Sales Outstanding79.483.581.8 K
Slightly volatile
Stock Based Compensation To Revenue0.110.09890.0756
Slightly volatile
Capex To Depreciation0.660.693.7189
Slightly volatile
EV To Sales5.295.5759.7272
Slightly volatile
Sales General And Administrative To Revenue0.250.20.2022
Slightly volatile
Average Inventory1.2 M1.6 M1.4 M
Slightly volatile
Research And Ddevelopement To Revenue0.560.591.1941
Slightly volatile
Capex To Revenue0.02460.02590.1629
Pretty Stable
Cash Per Share6.7911.055.0571
Slightly volatile
Intangibles To Total Assets0.09860.09390.0219
Slightly volatile
Current Ratio3.264.164.1797
Very volatile
Receivables Turnover4.754.521.4015
Slightly volatile
Capex Per Share0.170.180.1954
Slightly volatile
Average Receivables78.5 M81.2 M72.6 M
Slightly volatile
Revenue Per Share6.486.171.838
Slightly volatile
Interest Debt Per Share3.853.661.2579
Slightly volatile
Debt To Assets0.20.190.0675
Slightly volatile
Graham Number0.30.350.3767
Slightly volatile
Operating Cycle1201261.8 K
Slightly volatile
Ebt Per Ebit1.060.60.9686
Slightly volatile
Long Term Debt To Capitalization0.160.20.1564
Slightly volatile
Quick Ratio3.244.084.159
Very volatile
Net Income Per E B T0.821.010.8669
Slightly volatile
Cash Ratio1.860.931.2716
Slightly volatile
Cash Conversion Cycle56.859.799.5 K
Slightly volatile
Days Of Sales Outstanding79.483.581.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.31.261.2695
Slightly volatile
Fixed Asset Turnover2.313.584.6515
Slightly volatile
Debt Ratio0.20.190.0675
Slightly volatile
Price Sales Ratio5.185.4561.3511
Slightly volatile
Asset Turnover0.350.340.1525
Slightly volatile
Gross Profit Margin0.70.720.7517
Slightly volatile

Legend Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.5 B2.7 B2.8 B
Slightly volatile
Enterprise Value2.2 B2.7 B2.6 B
Slightly volatile

Legend Fundamental Market Drivers

Forward Price Earnings47.619
Cash And Short Term Investments1.1 B

Legend Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Legend Biotech Financial Statements

Legend Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Legend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue42.7 M27.3 M
Total Revenue721.3 M757.4 M
Cost Of Revenue269.8 M181.4 M
Stock Based Compensation To Revenue 0.10  0.11 
Sales General And Administrative To Revenue 0.20  0.25 
Research And Ddevelopement To Revenue 0.59  0.56 
Capex To Revenue 0.03  0.02 
Revenue Per Share 6.17  6.48 
Ebit Per Revenue(0.56)(0.58)

Pair Trading with Legend Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Legend Stock

  0.84DRTS Alpha Tau MedicalPairCorr
  0.8EQ EquilliumPairCorr
  0.8DSGN Design TherapeuticsPairCorr
  0.776C1 CytomX TherapeuticsPairCorr
  0.67DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:
How To Invest In Legend
Details
Is Legend Stock a good investment?
Details
What is Legend Biotech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Legend Biotech Correlation against competitors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.28)
Revenue Per Share
4.94
Quarterly Revenue Growth
0.7
Return On Assets
(0.07)
Return On Equity
(0.23)
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY